| Hazard Information | Back Directory | [Uses]
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model[1][2]. | [in vivo]
Ormutivimab (20 IU/kg; i.m.; single dose) protects beagles from a lethal challenge of street RABV BD06[1].
Ormutivimab (20 IU/kg, 100 IU/kg; i.m.; single dose) protects challenged Kunming mice against various rabies virus[1].
| Animal Model: | Balb/c mice challenge model with rabies virus[1] | | Dosage: | 20 IU/kg, 100 IU/kg | | Administration: | Intramuscular injection; single dose after 4 hr after infection | | Result: | Protected mice from rabies CVS-24 and GZ-1 isolates at a comparable rate (90%) to that of HRIG, human antirabies immune globulin. |
| [References]
[1] Zhai LL, et al. Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models. Travel Med Infect Dis. 2022 Mar-Apr;46:102267. DOI:10.1016/j.tmaid.2022.102267
[2] Zhang J, et al. Population Pharmacodynamic Analyses of Human Anti-Rabies Virus Monoclonal Antibody (Ormutivimab) in Healthy Adult Subjects. Vaccines (Basel). 2022 Jul 29;10(8):1218. DOI:10.3390/vaccines10081218 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|